SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

Conditions

• Type 1 Diabetes

Interventions

• COMBINATION_PRODUCT: Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
• COMBINATION_PRODUCT: Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
• DEVICE: No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
• DEVICE: No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks

Sponsor

Ananda Basu, MD

Collaborators

• [object Object]
• [object Object]
• [object Object]